Search
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawn[A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. … [L5971] However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.[L5974]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: DOXEPIN DURA T 50MG, DOXEPIN DURA T 100MGBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approvedCombination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist … The intention of substitution of illicit opioids with the long-acting opioids used in OAT is to prevent withdrawal symptomns for 24-36 hours following dosing to ultimately reduce cravings and drug-seeking
Mixtures: BUPRENORFINA E NALOXONE ETHYPHARM, BUPRENORFINA E NALOXONE ETHYPHARMCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOmega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalOmega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. … On September 8, 2004, the U.S. Food and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids.
Mixtures: Se-Tan DHA, Se-Tan DHABendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawnthe denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863. … a small handful of regions may continue to have the medication available for purchase and use either as a topical anti-inflammatory/analgesic cream or eye drop formulation.
Oxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].
Mixtures: OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 12 ADET, OLEDRO HOT D TEK DOZLUK EFERVESAN GRANÜL İÇEREN POŞET, 6 ADETCarbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigational[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier.
Mixtures: DOPADEX SR 50 MG/200 MG UZATILMIŞ SALIMLI TABLET,100 TB, DOPADEX SR 25 MG/100 MG UZATILMIŞ SALIMLI TABLET ,100 TBBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalCompared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. … [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Categories: Agents to Treat Airway DiseaseProducts: BROMURO DE TIOTROPIO 18 µG CÁPSULA, TIOSYNT BROMURO DE TIOTROPIO 18 MCG /POLVO PARA INHALACIONCilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States. … Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs.
Categories: Agents Acting on the Renin-Angiotensin System